LONG-TERM PROTON PUMP INHIBITOR THERAPY: IS IT REALLY SAFE? A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6140Keywords:
Proton Pump Inhibitors, PPI, Long-Term Therapy, Adverse Effects, Safety, Gastroesophageal Reflux DiseaseAbstract
Background: Proton pump inhibitors (PPIs) are among the most commonly prescribed medications worldwide and remain the cornerstone of treatment for acid-related gastrointestinal disorders. Despite their effectiveness and good safety profile, concerns have arisen regarding overuse and potential long-term adverse effects.
Aim: This review assessed the safety of long-term PPI therapy, summarized current evidence on adverse effects and addressed common misconceptions.
Material and methods: A narrative review of PubMed/MEDLINE and Google Scholar literature (2020–2026) was conducted, including key earlier studies. Priority was given to systematic reviews, meta-analyses, randomized trials and guidelines from ACG, AGA, NICE, FDA, and EMA.
Results: Long-term PPI use has been linked to vitamin B12 and iron deficiency, fractures, chronic kidney disease, Clostridioides difficile infection and possible cognitive impairment. However, most data are observational, and causality is unproven. Higher risk occurs in older adults, patients with comorbidities and those on prolonged high-dose therapy. Inappropriate prescribing and prolonged treatment without clear indications remain significant clinical concerns.
Conclusions: PPIs are effective and generally safe when used appropriately. Potential risks should not limit their use when indicated. Therapy should be individualized, regularly reassessed and use the lowest effective dose for the shortest duration.
References
Koyyada, A. (2021). Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie, 76(1), 13–21. https://doi.org/10.1016/j.therap.2020.06.019
Polish Register of Medicinal Products. (n.d.). Retrieved May 3, 2026, from https://rejestry.ezdrowie.gov.pl/rpl/search/public
Plehhova, K., Wray, J., Aluko, P., Sutton, S., McArdle, J., Dawson, A., Coyle, C., & Stevens, R. M. (2025). Prescribing practices for proton pump inhibitors among primary care physicians in England: An evaluation. BJGP Open, 9(2), BJGPO.2024.0059. https://doi.org/10.3399/BJGPO.2024.0059
Andrawes, M., Andrawes, W., Das, A., & Siau, K. (2025). Proton pump inhibitors (PPIs)—An evidence-based review of indications, efficacy, harms, and deprescribing. Medicina, 61(9), 1569. https://doi.org/10.3390/medicina61091569
Al-Aly, Z., Maddukuri, G., & Xie, Y. (2020). Proton pump inhibitors and the kidney: Implications of current evidence for clinical practice and when and how to deprescribe. American Journal of Kidney Diseases, 75(4), 497–507. https://doi.org/10.1053/j.ajkd.2019.07.012
Sandhu, D. S., & Fass, R. (2018). Current trends in the management of gastroesophageal reflux disease. Gut and Liver, 12(1), 7–16. https://doi.org/10.5009/gnl16615
Spechler, S. J. (2019). Proton pump inhibitors: What the internist needs to know. The Medical Clinics of North America, 103(1), 1–14. https://doi.org/10.1016/j.mcna.2018.08.001
Kahrilas, P., Anastasiou, F., Bredenoord, A. J., El Serag, H. B., Labenz, J., Mendive, J., Savarino, E. V., Sifrim, D., Udrescu, M., Yadlapati, R., & Hungin, A. P. (2024). Proton pump inhibitors: Rational use and use-reduction—The Windsor Workshop. Digestive Diseases, 42(3), 211–220. https://doi.org/10.1159/000538399
Katz, P. O., Dunbar, K. B., Schnoll-Sussman, F. H., Greer, K. B., Yadlapati, R., & Spechler, S. J. (2022). ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology, 117(1), 27–56. https://doi.org/10.14309/ajg.0000000000001538
National Institute for Health and Care Excellence. (2019). Gastro-oesophageal reflux disease and dyspepsia in adults: Investigation and management: Clinical guideline.
Wang, Z., Jin, J., Wang, G., Zhou, G., & Jiang, H. (2026). Systematic analysis of proton pump inhibitors-related adverse reactions using the FDA adverse event reporting system database. PLOS ONE, 21(2), e0340684. https://doi.org/10.1371/journal.pone.0340684
Dutta, A. K., Sharma, V., Jain, A., Elhence, A., Panigrahi, M. K., Mohta, S., … Makharia, G. K. (2025). Inappropriate use of proton pump inhibitors in clinical practice globally: A systematic review and meta-analysis. Gut, 74(1), e5–e5.
Othman, F., Card, T. R., & Crooks, C. J. (2016). Proton pump inhibitor prescribing patterns in the UK: A primary care database study. Pharmacoepidemiology and Drug Safety, 25(9), 1079–1087.
Bhatnagar, M. S., Choudhari, S., Pawar, D., & Sharma, A. (2024). Long-term use of proton-pump inhibitors: Unravelling the safety puzzle. Cureus, 16(1), e52773. https://doi.org/10.7759/cureus.52773
Jaynes, M., & Kumar, A. B. (2018). The risks of long-term use of proton pump inhibitors: A critical review. Therapeutic Advances in Drug Safety, 10, 2042098618809927. https://doi.org/10.1177/2042098618809927
Ambizas, E. M., & Etzel, J. V. (2017). Proton pump inhibitors: Considerations with long-term use. US Pharmacist, 42(7), 4–6.
Ward, R. M., & Kearns, G. L. (2013). Proton pump inhibitors in pediatrics: Mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatric Drugs, 15(2), 119–131. https://doi.org/10.1007/s40272-013-0012-x
El Rouby, N., Lima, J. J., & Johnson, J. A. (2018). Proton pump inhibitors: From CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism & Toxicology, 14(4), 447–460. https://doi.org/10.1080/17425255.2018.1461835
Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22), 2435–2442. https://doi.org/10.1001/jama.2013.280490
Attwood, S. E., Ell, C., Galmiche, J. P., Fiocca, R., Hatlebakk, J. G., Hasselgren, B., Långström, G., Jahreskog, M., Eklund, S., Lind, T., & Lundell, L. (2015). Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Alimentary Pharmacology & Therapeutics, 41(11), 1162–1174. https://doi.org/10.1111/apt.13194
Shikata, T., Sasaki, N., Ueda, M., Kimura, T., Itohara, K., Sugahara, M., Fukui, M., Manabe, E., Masuyama, T., & Tsujino, T. (2015). Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients. Circulation Journal, 79(1), 193–200. https://doi.org/10.1253/circj.CJ-14-0582
Zhou, B., Huang, Y., Li, H., Sun, W., & Liu, J. (2016). Proton-pump inhibitors and risk of fractures: An update meta-analysis. Osteoporosis International, 27(1), 339–347. https://doi.org/10.1007/s00198-015-3365-x
Fraser, L. A., Leslie, W. D., Targownik, L. E., Papaioannou, A., Adachi, J. D., & CaMos Research Group. (2013). The effect of proton pump inhibitors on fracture risk: Report from the Canadian Multicenter Osteoporosis Study. Osteoporosis International, 24(4), 1161–1168. https://doi.org/10.1007/s00198-012-2112-9
van der Hoorn, M. M. C., Tett, S. E., de Vries, O. J., Dobson, A. J., & Peeters, G. M. E. E. G. (2015). The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone, 81, 675–682. https://doi.org/10.1016/j.bone.2015.08.024
Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E. (2016). Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine, 176(2), 238–246. https://doi.org/10.1001/jamainternmed.2015.7193
Antoniou, T., Macdonald, E. M., Hollands, S., Gomes, T., Mamdani, M. M., Garg, A. X., Paterson, J. M., & Juurlink, D. N. (2015). Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open, 3(2), E166–E171. https://doi.org/10.9778/cmajo.20140074
Engstrand, L., & Graham, D. Y. (2020). Microbiome and gastric cancer. Digestive Diseases and Sciences, 65(3), 865–873. https://doi.org/10.1007/s10620-020-06101-z
Janarthanan, S., Ditah, I., Adler, D. G., & Ehrinpreis, M. N. (2012). Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. The American Journal of Gastroenterology, 107(7), 1001–1010. https://doi.org/10.1038/ajg.2012.179
Trifan, A., Stanciu, C., Girleanu, I., Stoica, O. C., Singeap, A. M., Maxim, R., Chiriac, S. A., Ciobica, A., & Boiculese, L. (2017). Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World Journal of Gastroenterology, 23(35), 6500–6515. https://doi.org/10.3748/wjg.v23.i35.6500
Su, T., Lai, S., Lee, A., He, X., & Chen, S. (2018). Meta-analysis: Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. Journal of Gastroenterology, 53(1), 27–36. https://doi.org/10.1007/s00535-017-1371-9
Xu, H. B., Wang, H. D., Li, C. H., Ye, S., Dong, M. S., Xia, Q. J., Zhang, A. Q., Pan, K., Ge, X. L., & Dong, J. H. (2015). Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis. Genetics and Molecular Research: GMR, 14(3), 7490–7501. https://doi.org/10.4238/2015.July.3.25
Ortiz-Guerrero, G., Amador-Muñoz, D., Calderón-Ospina, C. A., López-Fuentes, D., & Nava Mesa, M. O. (2018). Proton pump inhibitors and dementia: Physiopathological mechanisms and clinical consequences. Neural Plasticity, 2018, 5257285. https://doi.org/10.1155/2018/5257285
Haenisch, B., von Holt, K., Wiese, B., Prokein, J., Lange, C., Ernst, A., Brettschneider, C., König, H. H., Werle, J., Weyerer, S., Luppa, M., Riedel-Heller, S. G., Fuchs, A., Pentzek, M., Weeg, D., Bickel, H., Broich, K., Jessen, F., Maier, W., & Scherer, M. (2015). Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry and Clinical Neuroscience, 265(5), 419–428. https://doi.org/10.1007/s00406-014-0554-0
Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Störk, S., Branch, K. R. H., Bhatt, D. L., Verhamme, P. B., O'Donnell, M., Maggioni, A. P., Lonn, E. M., Piegas, L. S., Ertl, G., Keltai, M., Bruns, N. C., … COMPASS Investigators. (2019). Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology, 157(3), 682–691.e2. https://doi.org/10.1053/j.gastro.2019.05.056
Desai, M., Nutalapati, V., Srinivasan, S., Fathallah, J., Dasari, C., Chandrasekhar, V. T., Mohammad, B., Kohli, D., Vaezi, M., Katz, P. O., & Sharma, P. (2020). Proton pump inhibitors do not increase the risk of dementia: A systematic review and meta-analysis of prospective studies. Diseases of the Esophagus, 33(10), doaa041. https://doi.org/10.1093/dote/doaa041
Li, M., Luo, Z., Yu, S., & Tang, Z. (2019). Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine, 98(7), e14422. https://doi.org/10.1097/MD.0000000000014422
Freedberg, D. E., Kim, L. S., & Yang, Y. X. (2017). The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology, 152(4), 706–715. https://doi.org/10.1053/j.gastro.2017.01.031
Nassar, Y., & Richter, S. (2018). Proton-pump inhibitor use and fracture risk: An updated systematic review and meta-analysis. Journal of Bone Metabolism, 25(3), 141–151. https://doi.org/10.11005/jbm.2018.25.3.141
Cheungpasitporn, W., Thongprayoon, C., Kittanamongkolchai, W., Srivali, N., Edmonds, P. J., Ungprasert, P., O'Corragain, O. A., Korpaisarn, S., & Erickson, S. B. (2015). Proton pump inhibitors linked to hypomagnesemia: A systematic review and meta-analysis of observational studies. Renal Failure, 37(7), 1237–1241. https://doi.org/10.3109/0886022X.2015.1057800
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J., Dijkstra, G., Franke, L., Xavier, R. J., Jonkers, D., Wijmenga, C., Weersma, R. K., & Zhernakova, A. (2016). Proton pump inhibitors affect the gut microbiome. Gut, 65(5), 740–748. https://doi.org/10.1136/gutjnl-2015-310376
Clooney, A. G., Bernstein, C. N., Leslie, W. D., Vagianos, K., Sargent, M., Laserna-Mendieta, E. J., Claesson, M. J., & Targownik, L. E. (2016). A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 43(9), 974–984. https://doi.org/10.1111/apt.13568
Maes, M. L., Fixen, D. R., & Linnebur, S. A. (2017). Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence. Therapeutic Advances in Drug Safety, 8(9), 273–297. https://doi.org/10.1177/2042098617715381
Pakkir Maideen, N. M., Jumale, A., & Balasubramaniam, R. (2017). Drug interactions of metformin involving drug transporter proteins. Advanced Pharmaceutical Bulletin, 7(4), 501–505. https://doi.org/10.15171/apb.2017.062
Savarino, V., Marabotto, E., Zentilin, P., Furnari, M., Bodini, G., De Maria, C., Pellegatta, G., Coppo, C., & Savarino, E. (2018). Proton pump inhibitors: Use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 11(11), 1123–1134. https://doi.org/10.1080/17512433.2018.1531703
Sattayalertyanyong, O., Thitilertdecha, P., & Auesomwang, C. (2020). The inappropriate use of proton pump inhibitors during admission and after discharge: A prospective cross-sectional study. International Journal of Clinical Pharmacy, 42(1), 174–183. https://doi.org/10.1007/s11096-019-00955-8
Boster, J., Lowry, L. E., Bezzant, M. L., Kuiper, B., & Surry, L. (2020). Reducing the inappropriate use of proton pump inhibitors in an internal medicine residency clinic. Cureus, 12(1), e6609. https://doi.org/10.7759/cureus.660
Targownik, L. E., Fisher, D. A., & Saini, S. D. (2022). AGA clinical practice update on de-prescribing of proton pump inhibitors: Expert review. Gastroenterology, 162(4), 1334–1342. https://doi.org/10.1053/j.gastro.2021.12.247
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Alicja Smolińska, Maria Bołoz, Izabela Grzyb, Jan Szewczyk, Sylwia Haba, Ewa Dapkiewicz, Dawid Gąsowski, Katarzyna Łysynkiewicz, Zuzanna Wątek, Patrycja Krawczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
